Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1627929-55-8
Formula :	C₂₆H₂₂N₄O₃
M.W :	438.48
SMILES Code :	O=C(O)C1=CC=C(C2=CN([C@H](C3=NC=CC=C3)C)C4=CC(C5=C(C)ON=C5C)=CN=C42)C=C1
MDL No. :	MFCD31657388
InChI Key :	AMSUHYUVOVCWTP-INIZCTEOSA-N
Pubchem ID :	90448953

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

DLBCL cell lines (SUDHL6, OCI-LY1, OCI-LY8, DOHH2)	1000 nM	48 hours	In BCL-2-high DLBCL cell lines, PLX51107 and PLX2853 showed limited efficacy alone but exhibited synergistic effects when combined with the BH3 mimetic ABT199, significantly enhancing apoptosis.	Blood Adv. 2020 Jul 28;4(14):3316-3328.
HBLAK	0.6 µM	72 hours	PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells	Cancers (Basel). 2021 Mar 18;13(6):1376.
UM-UC-3	8.8 µM	72 hours	PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells	Cancers (Basel). 2021 Mar 18;13(6):1376.
VM-CUB1	2 µM	72 hours	PLX51107 inhibited cell growth, caused DNA damage, and blocked DNA repair response in UC cells	Cancers (Basel). 2021 Mar 18;13(6):1376.
THJ-16T cells	500 nM	5 days	Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-16T cells, reducing cell numbers by 88.4%.	Endocr Relat Cancer. 2019 Sep;26(9):739-750.
THJ-11T cells	500 nM	5 days	Evaluate the effect of PLX on cell proliferation, results showed that PLX inhibited the proliferation of THJ-11T cells, reducing cell numbers by 88.9%.	Endocr Relat Cancer. 2019 Sep;26(9):739-750.
Primary CLL cells	1μM	4 hours	To assess the effect of PLX51107 on BRD4 binding, results showed significant reduction in BRD4 load at enhancer regions	Cancer Discov. 2018 Apr;8(4):458-477.
Omm1.3 cells	0.5 μmol/L	48 hours	Validate the synergistic effect of PTL with PLX51107, inhibiting NF-κB signaling and inducing apoptosis.	Cancer Res. 2019 May 1;79(9):2415-2425.
92.1 cells	0.04-5 μmol/L	72 hours	Evaluate the combinatorial therapeutic effects of PLX51107 with a compound library, identifying NF-κB inhibitors PTL and PDTC as synergistic with PLX51107.	Cancer Res. 2019 May 1;79(9):2415-2425.
OCI-AML3	1 µM	96 hours	To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability	Exp Hematol Oncol. 2024 Mar 4;13(1):27.
MOLM-13	1 µM	96 hours	To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability	Exp Hematol Oncol. 2024 Mar 4;13(1):27.
MV4-11	1 µM	96 hours	To evaluate the effect of PLX51107 on AML cell viability, results showed that PLX51107 reduced AML cell viability	Exp Hematol Oncol. 2024 Mar 4;13(1):27.
M238 cells	1, 2, and 4 μM	24 hours to 3 weeks	PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of M238 cells and reduced S-phase entry.	Br J Cancer. 2020 Mar;122(6):789-800.
1205Lu cells	1, 2, and 4 μM	24 hours to 3 weeks	PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of 1205Lu cells and reduced S-phase entry.	Br J Cancer. 2020 Mar;122(6):789-800.
A375 cells	1, 2, and 4 μM	24 hours to 3 weeks	PLX51107 combined with BRAFi/MEKi significantly inhibited the growth of A375 cells and reduced S-phase entry.	Br J Cancer. 2020 Mar;122(6):789-800.
OCI-AML3 cells	250 nM	3 hours	Evaluate the inhibitory effect of PLX51107 on MYC expression	Haematologica. 2021 Apr 1;106(4):1022-1033.
MOLM-14 cells	79 nM		Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells	Haematologica. 2021 Apr 1;106(4):1022-1033.
MV4-11 cells	62 nM		Evaluate the inhibitory effect of PLX51107 on FLT3-ITD mutated AML cells	Haematologica. 2021 Apr 1;106(4):1022-1033.
Em-myc lymphoma cell lines	1000 nM	48 hours	PLX51107 and PLX2853 induced apoptosis by upregulating BIM protein and suppressing the miR-17~92 cluster, resulting in cytotoxic responses in BCL-2-low MYC-driven lymphomas.	Blood Adv. 2020 Jul 28;4(14):3316-3328.
Rheumatoid arthritis patient CD14+ monocytes	50, 250 nM	48 hours	To evaluate the effect of PLX51107 on FcγR expression in monocytes from rheumatoid arthritis patients. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, FcγRIIIa, and γ chain mRNA expression, while upregulating FcγRIa expression.	Int J Mol Sci. 2023 Apr 21;24(8):7623.
Healthy donor CD14+ monocytes	50, 100, 200, 250 nM	24 hours	To evaluate the effect of PLX51107 on the transcriptional expression of FcγRIIa, FcγRIIb, FcγRIIIa, and FcεRIγ. Results showed that PLX51107 significantly downregulated FcγRIIa, FcγRIIb, and FcγRIIIa mRNA expression, while upregulating FcγRIa expression.	Int J Mol Sci. 2023 Apr 21;24(8):7623.

Nude mice	Xenograft model	Oral	24 mg/kg/day	Once daily for 24 days or 48 days	Evaluate the inhibitory effect of PLX on tumor growth, results showed that PLX significantly inhibited the growth of xenograft tumors.	Endocr Relat Cancer. 2019 Sep;26(9):739-750.
Mice	Eμ-TCL1 transgenic mouse model	Oral gavage	20 mg/kg	Once daily for eight days	To assess the effect of PLX51107 on leukemia burden, results showed significant reduction in leukemic cells in peripheral blood and spleen	Cancer Discov. 2018 Apr;8(4):458-477.
Athymic nu/nu mice	R-Omm1.3 xenograft model	Oral and intraperitoneal injection	20 mg/kg orally	Three times a week for 5 weeks	Evaluate the effect of PLX51107 combined with PTL on BETi-resistant tumors, showing significant inhibition of tumor growth.	Cancer Res. 2019 May 1;79(9):2415-2425.
NSG mice	MOLM-13-luciferase xenograft model	Oral gavage	20 mg/kg	Daily administration until the end of the experiment	To evaluate the anti-leukemic effect of PLX51107 in vivo, results showed that PLX51107 significantly prolonged the survival of mice	Exp Hematol Oncol. 2024 Mar 4;13(1):27.
Nude mice	1205Lu and A375 xenograft models	Oral	90 ppm	Intermittent dosing (2 days on/5 days off)	Intermittent PLX51107 combined with BRAFi/MEKi treatment significantly delayed tumor recurrence and improved animal survival.	Br J Cancer. 2020 Mar;122(6):789-800.
SCID mice	MV4-11 xenograft model	Oral	10, 20, 40 mg/kg	Once daily for 14 days	Evaluate the anti-tumor effect of PLX51107 as a single agent in FLT3-ITD AML xenograft model	Haematologica. 2021 Apr 1;106(4):1022-1033.
Mice	Em-myc lymphoma model	Oral gavage	10 mg/kg	Once daily, 5 consecutive days/week	PLX51107 and PLX2853 showed significant therapeutic effects in wild-type Em-myc lymphoma models but limited efficacy in BCL-2-high models. Combination with the BH3 mimetic ABT199 significantly enhanced tumor control.	Blood Adv. 2020 Jul 28;4(14):3316-3328.
DBA mice	Collagen-induced arthritis model	Oral gavage	10 mg/kg	Three times per week for 5 weeks	To evaluate the effect of PLX51107 on FcγR expression and arthritis symptoms in vivo. Results showed that PLX51107 significantly reduced footpad swelling and downregulated FcγR expression in monocytes and macrophages in the spleen.	Int J Mol Sci. 2023 Apr 21;24(8):7623.
Mice	BrafV600E, Ptennull, Cdkn2dnul1 YUMM1.7 tumor model	Oral	557-1500 ng/ml	12 days	PLX51107 significantly delayed melanoma growth, reduced the frequency of tumor-infiltrating Tregs, increased the CD8/Tregs ratio, and decreased PD1 expression on CD8+ T cells. Combined with anti-PD-L1, it significantly inhibited tumor growth.	J Invest Dermatol. 2019 Jul;139(7):1612-1615

{[proInfo.proName]}

CAS No.: 1627929-55-8

{[proInfo.proName]}

CAS No.: 1627929-55-8

Alternative Products

Product Details of PLX51107

Safety of PLX51107

Related Pathways of PLX51107

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.28mL 0.46mL 0.23mL	11.40mL 2.28mL 1.14mL	22.81mL 4.56mL 2.28mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed